NewAmsterdam Pharma Company NAMS Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$203.82M+15.6% | -$241.6M-36.5% | -$176.94M-682% | -$22.63M+45.8% | ||
| $220K+94.7% | $113K+131% | $49K+444% | $9K+80.0% | ||
| $59.43M+76.8% | $33.62M+36.8% | $24.57M+497% | $4.12M+231% | ||
| -$147.78M+6.8% | -$158.56M-12.3% | -$141.22M-1,424% | $10.67M+136% | ||
| $246K-63.4% | $672K+2,700% | $24K-89.1% | $221K+821% | ||
| -$177.42M-182% | -$62.85M-261,767% | -$24K+89.1% | -$221K-821% | ||
| $29.52M-95.5% | $659.51M+7,300% | $8.91M-97.7% | $391.91M+363% | ||
| -$293.18M— | —— | -$132.33M-133% | $402.35M+629% | ||
| -$148.03M+7.0% | -$159.24M-12.7% | -$141.24M-1,452% | $10.44M+135% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does NewAmsterdam Pharma Company's cash flow data come from?
- Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.